Switch to
Predicate | Object |
---|---|
rdf:type | |
calbc:hasCorrelation | |
skos:definition |
NCI: A monoclonal antibody that is being studied in the treatment of cancer. Monoclonal antibodies are produced in the laboratory and can locate and bind to cancer cells.,PDQ: A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322808&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322808&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_The
|
skos:inScheme | |
skos-xl:prefLabel | |
skos-xl:altLabel |
umls-label:A19034274,
umls-label:A20830775,
umls-label:A20834981,
umls-label:A20837212,
umls-label:A4361525,
umls-label:A6959619,
umls-label:A16758238,
umls-label:A20894790,
umls-label:A20897608,
umls-label:A20893463,
umls-label:A7658540,
umls-label:A20834980,
umls-label:A4361659,
umls-label:A11919568,
umls-label:A11915583,
umls-label:A10789633
|